Galaxy Medicare IPO is a fresh issue and offer for sale scheduled to open on September 10, 2025, and close on September 12, 2025. The IPO price band is set between ₹51 and ₹54 per share with a face value of ₹10. Galaxy Medicare is a leading manufacturer and exporter of medical devices and Plaster of Paris bandages, holding 27 registered trademarks. Galaxy Medicare IPO provides investors an opportunity to participate in the growing healthcare consumables market driven by quality products and steady revenue growth.
₹00
₹54
₹54.00
Expert Opinions
Market sentiment for Galaxy Medicare IPO is positive, reflecting investor interest in the growing healthcare consumables sector. The company’s strengths include a diversified product portfolio with 27 registered trademarks, certified quality standards (ISO 13485:2016 and CE), and a strong distribution network serving both domestic hospitals and international markets. Risks involve dependency on regulatory approvals, market competition, and raw material price fluctuations.
Valuation analysis of the financial year 2024 for Galaxy Medicare IPO highlights a robust Return on Equity (ROE) of 23.85%, Return on Capital Employed (ROCE) of 23.80%, and a Net Asset Value (NAV) of ₹13.10, demonstrating healthy profitability and asset utilization. From a long-term investment perspective, Galaxy Medicare is well poised to benefit from increasing demand for medical devices and surgical dressings in India and abroad.
Investor Considerations
Galaxy Medicare IPO has showcased solid company performance and strong fundamentals with revenue growth from ₹32.03 crore in FY 2023 to ₹36.94 crore in FY 2024. The healthcare consumables sector outlook remains favorable due to increasing demand for quality medical supplies domestically and internationally. The Galaxy Medicare IPO valuation for FY 2024 reflects a Price to Book Value of 3.84, PAT margin of 10.26%, and a Debt to Equity ratio of 0.52, indicating healthy profitability and moderate leverage.
Growth prospects are promising with plans for capacity expansion, enhanced product range, and an expanding client base. Risks include regulatory changes, raw material price fluctuations, and competition. Investors with long-term goals may capitalize on structural industry growth, while short-term investors should consider market volatility and SME segment characteristics.
| Date | GMP | Trend |
|---|---|---|
| 16 Sep 2025 11.38 | ₹00 | --- |
| 15 Sep 2025 11.35 | ₹00 | --- |
| 13 Sep 2025 11.04 | ₹00 | --- |
| 12 Sep 2025 15.58 | ₹00 | Down |
| 11 Sep 2025 11.09 | ₹5 | Up |
| 10 Sep 2025 20.17 | ₹00 | --- |
| 09 Sep 2025 11.25 | ₹00 | --- |
| 08 Sep 2025 15.22 | ₹00 | --- |
FAQs
The Grey Market Premium showed good accuracy in predicting Galaxy Medicare IPO’s listing performance. With a final GMP of ₹0, it projected no premium over the issue price of ₹54. The stock listed exactly at ₹54, delivering 0% gain. This resulted in zero prediction error, where the GMP correctly signaled a flat listing and closely aligned with the actual outcome, reflecting strong reliability in this case.
Galaxy Medicare IPO Current GMP is ₹00.
Galaxy Medicare IPO Expected Returns is 0.00%.
Galaxy Medicare IPO estimated listing price is ₹54.